MindVision Q1 CBM

12345678910111213
Across
  1. 2. Ready to use and prevents contamination
  2. 6. The gap between two tablets should be >2 hours
  3. 7. Synergistic combination with small tablet size
  4. 8. A class of SPARI, an antidepressant
  5. 10. Minimal effects on glucose lipids and Prolactin
  6. 12. API size <20 micron size
  7. 13. FDA approved in migraine prophylaxis
Down
  1. 1. Offers synergy... Improves outcome
  2. 3. The brand manufactured by Matrix technology
  3. 4. Indicated in IBS and FD
  4. 5. AB rated manufacturing plant
  5. 9. Noncompetitive inhibitor of AMPA receptor and prevents epilepsy
  6. 11. 90% Response rate and 74% Remission rate